Browsing by Author "Quentin Gilleman"

Now showing 1 - 2 of 2

Clinical Research on Neglected Tropical Diseases: Challenges and Solutions
(Public Library of Science, 2016) Marleen Boelaert; The NIDIAG Consortium; Barbara Barbé; Emmanuel Bottieau; Christophe Burm; Philippe Büscher; Jozefien Buyze; Stijn Deborggraeve; Koen De Winne; Philippe Gillet; David Hendrickx; Arabella Huys; Jan Jacobs; Veerle Lejon; Filip Meheus; Joris Menten; Evelien Paessens; Katja Polman; Raffaella Ravinetto; Stijn Rogé; Céline Schurmans; Achilleas Tsoumanis; Johan Van Griensven; Harry van Loen; Kristien Verdonck; Cédric Yansouni; François Chappuis; Emilie Alirol; Ninon S. Horié; Suman Rijal; Nisha K. Bhatta; Narayan R. Bhattarai; Prahlad Karki; Basudha Khanal; Kanika Koirala; Bickram Pradhan; Surendra Uranw; Jürg Utzinger; Sören L. Becker; Martin W. Bratschi; Justin K. Chatigre; Jean T. Coulibaly; Jean-Paul Gohou; Mathias Herrmann; Stefanie Knopp; Hanspeter Marti; Eliézer K. N’Goran; Beatrice Nickel; Pierre H.H. Schneeberger; Kigbafori D. Silué; Peter Steinmann; Lutz von Müller; Penelope Vounatsou; Joel A. Yao; Patrick K. Yao; Peiling Yap; Pascal Lutumba; Claude Basilua; Edmonde Bonebe; Gustave Bukasa; Sebastien Inamba; Jean Roger Kalo Lilo; Vincent Kambale; Tharcisse Kayembe; Octavie Lunguya; Maria Mashako; Luigi Mininkulu; Alain Mpanya; Deby Mukendi; Dieudonné Mumba; Jean-Jacques Muyembe; Pati Pyan; Sayda El-Safi; Mannar Abdel-Rahman; Saad Ageed Al farazdag; Atia Atia; Abdallah Bashir; Ahmed Bashir; Mohammed Bashir; Mohamedelfateh Eljack; Alhabib Elhabib; Husam Elshikh; Awad Hammad; Mohammed Issa; Mohamed S. Mohamed; Mohammed O. Mohammedali; Salah Mohammed Ali; Modether Morsal; Shawgi Hago Almugadam; Lim Kruy; P. Maling Ellen; Leng Long; Manoza Maricel; Saman Ratanakneary; Bouy Sok; Sok Sopheak; Ros Sreyphors; Teav Syna; Sopheak Thai; Phe Thong; So Veasna; Che Yanith; Michael Miles; Tapan Bhattacharyya; Sakib Burza; Graham Clark; Andrew Falconar; Tegwen Marlais; Adelaide Michaels; Rosanna Peeling; Matthew Yeo; Shyam Sundar; Shahnawaj Alam; Jaya Chakravarty; Poonam Kumari; Madhukar Rai; Deepak K. Verma; Pascal Mertens; Stéphane Degallaix; Laurence Denorme; Quentin Gilleman; Thierry Leclipteux; Thomas Simon; Caroline Thunissen; Moussa Sacko; Cheik O. Coulibaly; Birama D. Diakité; Mama N. Doumbia; Aly Landouré; Rénion Saye; Mamadou S. Traoré; Hassan K.M. Fofana; Yodi Mahendradhata; Riris A. Ahmad; Bintari Dwihardiani; Norma S. Hurif; Rizqiani A. Kusumasari; Fransiska Meyanti; Elsa H. Murhandarwati; Haripurnomo Kushadiwijaya; Trisasi Lestari; Irene M. Rahakbauw; Ratih Restiani; Supargiyono; Henry Surendra; Mohamad Syairaji; Jarir A. Thobari
[No abstract available]
Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse, and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis
(Frontiers Media S.A., 2018) Tegwen Marlais; Tapan Bhattacharyya; Om Prakash Singh; Pascal Mertens; Quentin Gilleman; Caroline Thunissen; Bruno C. Bremer Hinckel; Callum Pearson; Bathsheba L. Gardner; Stephanie Airs; Marianne de la Roche; Kiera Hayes; Hannah Hafezi; Andrew K. Falconar; Osama Eisa; Alfarazdeg Saad; Basudha Khanal; Narayan Raj Bhattarai; Suman Rijal; Marleen Boelaert; Sayda El-Safi; Shyam Sundar; Michael A. Miles
Background: There is a recognized need for an improved diagnostic test to assess post-chemotherapeutic treatment outcome in visceral leishmaniasis (VL) and to diagnose post kala-azar dermal leishmaniasis (PKDL). We previously demonstrated by ELISA and a prototype novel rapid diagnostic test (RDT), that high anti-Leishmania IgG1 is associated with post-treatment relapse versus cure in VL. Methodology: Here, we further evaluate this novel, low-cost RDT, named VL Sero K-SeT, and ELISA for monitoring IgG1 levels in VL patients after treatment. IgG1 levels against L. donovani lysate were determined. We applied these assays to Indian sera from cured VL at 6 months post treatment as well as to relapse and PKDL patients. Sudanese sera from pre- and post-treatment and relapse were also tested. Results: Of 104 paired Indian sera taken before and after treatment for VL, when deemed clinically cured, 81 (77.9%) were positive by VL Sero K-SeT before treatment; by 6 months, 68 of these 81 (84.0%) had a negative or reduced RDT test line intensity. ELISAs differed in positivity rate between pre- and post-treatment (p = 0.0162). Twenty eight of 33 (84.8%) Indian samples taken at diagnosis of relapse were RDT positive. A comparison of Indian VL Sero K-SeT data from patients deemed cured and relapsed confirmed that there was a significant difference (p < 0.0001) in positivity rate for the two groups using this RDT. Ten of 17 (58.8%) Sudanese sera went from positive to negative or decreased VL Sero K-SeT at the end of 11–30 days of treatment. Forty nine of 63 (77.8%) PKDL samples from India were positive by VL Sero K-SeT. Conclusion: We have further shown the relevance of IgG1 in determining clinical status in VL patients. A positive VL Sero K-SeT may also be helpful in supporting diagnosis of PKDL. With further refinement, such as the use of specific antigens, the VL Sero K-SeT and/or IgG1 ELISA may be adjuncts to current VL control programmes. © Copyright © 2018 Marlais, Bhattacharyya, Singh, Mertens, Gilleman, Thunissen, Hinckel, Pearson, Gardner, Airs, de la Roche, Hayes, Hafezi, Falconar, Eisa, Saad, Khanal, Bhattarai, Rijal, Boelaert, El-Safi, Sundar and Miles.